SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa

by Ysios Capital

SparingVision today announces a key advancement in its Phase I/II clinical trial for SPVN06, the Company’s lead gene-agnostic investigational gene therapy for the treatment of retinitis pigmentosa (...

Read more

SparingVision Selects Second Target in Strategic Collaboration with Intellia Therapeutics

by Ysios Capital

SparingVision today announces that it has selected a second target as part of its strategic collaboration with Intellia Therapeutics, Inc.to develop novel genomic medicines utilizing CRISPR-based gene...

Read more

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics

by Ysios Capital

SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for eye diseases, today announced that it has sold its ex vivo GIRK technology to Tenpoint Therapeutics.

Read more

SparingVision Raises €44.5 Million in a round led by 4BIO Capital and UPMC Enterprises, and included Jeito Capital and Ysios Capital

by Ysios Capital

SparingVision (“the Company”), a genomic medicine company focused on ocular diseases, today announces a €44.5 million financing round. The round was led by 4BIO Capital (“4BIO”) and UPMC Ent...

Read more
Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Photos Stream